Self-Reported Pharmacogenetic Medication Use in the Our Future Health Cohort.

ABSTRACT: The aim of this study was to describe self-reported use of medications with established pharmacogenetic guidance in the Our Future Health (OFH) cohort. We examined four key pharmacogenes-CYP2C19, CYP2C9, CYP2D6, and SLCO1B1-and medications supported by strong evidence for clinical actionability according to the Clinical Pharmacogenetics Implementation Consortium (CPIC). Self-reported medication use was summarized, concurrent use assessed, and findings stratified by age, sex, and ethnicity. We studied these data in 1.78 million OFH participants included in the June 2025 release. The cohort was 57.3% female, aged 18-95 years (mean 53.1 years), with 90.2% self-identifying as "White." Eighteen medication groups were explicitly listed in the baseline questionnaire, enabling identification of ex

SUBMITTER: Dixon P 

PROVIDER: S-EPMC12790112 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature